荧光原位杂交检测胃癌中HER-2基因状态  

Evaluation of HER-2 gene expression status in gastric carcinoma by fluorescence in situ hybridization

作　　者：李亚卓[1] 李冰[1] 赵坡[1] 

机构地区：[1]解放军总医院病理科

出　　处：《诊断病理学杂志》2009年第3期171-173,共3页Chinese Journal of Diagnostic Pathology

摘　　要：目的探讨胃癌中HER-2基因扩增与HER-2蛋白过表达的关系。方法运用免疫组化（IHC）和荧光原位杂交（FISH）技术,对手术切除的84例胃癌石蜡标本进行HER-2状态的检测。结果84例中,19例HER-2蛋白（＋）（22.6%）,其中HER-2基因扩增7例（8.3%） 12例HER-2蛋白（/）（14.3%）中,HER-2基因扩增5例（6%）,占高表达组的41.7% 72例HER-2蛋白（＋/0）（85.8%）中,HER-2基因扩增2例（2.4%）。结论HER-2蛋白（/）与HER-2基因扩增密切相关,故这类患者可考虑先做IHC初步筛选,再做FISH确诊,从而为胃癌分子靶向治疗提供有价值的信息。Objective To investigate the correlation between HER-2 gene amplification and HER-2 protein overexpression. Methods HER-2 status in the surgically removed tissues of 84 gastric carcinoma eases was evaluated by using immunohistochemistry （IHC） and fluorescence in situ hybridization （FISH） methods. Results The percentages of HER-2 protein expression and HER-2 gene amplification were 22.6% （19/84） and 8.3% （7/84） in 84 patients with gastric cancer. Among the 84 eases, 12 （ 14.3 % ） eases showed HER-2 overexpression （3 ＋/2 ＋ ） by IHC and 5 （6.0 % ） cases showed HER-2 amplification by FISH. Two （2.4%） of the 72 cases with low or negative HER-2 expression （1 ＋ or 0） showed HER-2 amplification. whereas the ratio of HER-2 gene amplification was 41.7% （5/12） among patients with HER-2 protein overexpression. Condusions The correlation between HER-2 protein overexpression and HER-2 gene amplification is statistically significant. Therefore immunohistochemistry can be regarded as an initial screening method for HER-2 expression status, and then FISH testing should be done as well. It is useful for molecular target therapy to detect HER-2 status in gastric carcinoma.

关 键 词：胃肿瘤 荧光原位杂交 ERBB-2 基因扩增 

分 类 号：R735.2[医药卫生—肿瘤]